Gilles TRAVE

Dr. Gilles TRAVE


Research Focus & Metrics

Representative Publications

View All Publications
20 January 2016 in Nature
Verified
Journal Article
Open access
PDF file
DMDenise Martinez-Zapien
Denise Martinez-Zapien
Francesc Xavier RuizFrancesc Xavier Ruiz
Francesc Xavier Ruiz
JPJuline Poirson
Juline Poirson
AMAndré Mitschler
André Mitschler
JRJuan Ramirez
Juan Ramirez
KZKatia Zanier
Katia Zanier
WebStructural details of how oncogenic human papilloma viruses induce cancer by targeting the tumour suppressor p53 for ubiquitin-mediated degradation. Oncogenic human papillomaviruses induce cancer by targeting the tumour suppressor p53 for ubiquitin-mediated degradation. Katia Zanier and colleagues now reveal structural details of how this viral hijacking occurs. They solve the structure of a ternary complex revealing the interaction between the HPV16 oncoprotein E6, the LxxLL motif of the cellular ubiquitin ligase E6AP, and the core domain of p53. The p53 pro-apoptotic tumour suppressor is mutated or functionally altered in most cancers. In epithelial tumours induced by ‘high-risk’ mucosal human papilloma viruses, including human cervical carcinoma and a growing number of head-and-neck cancers1, p53 is degraded by the viral oncoprotein E6 (ref. 2). In this process, E6 binds to a short leucine (L)-rich LxxLL consensus sequence within the cellular ubiquitin ligase E6AP3. Subsequently, the E6/E6AP heterodimer recruits and degrades p53 (ref. 4). Neither E6 nor E6AP are separately able to recruit p53 (refs 3, 5), and the precise mode of assembly of E6, E6AP and p53 is unknown. Here we solve the crystal structure of a ternary complex comprising full-length human papilloma virus type 16 (HPV-16) E6, the LxxLL motif of E6AP and the core domain of p53. The LxxLL motif of E6AP renders the conformation of E6 competent for interaction with p53 by structuring a p53-binding cleft on E6. Mutagenesis of critical positions at the E6–p53 interface disrupts p53 degradation. The E6-binding site of p53 is distal from previously described DNA- and protein-binding surfaces of the core domain. This suggests that, in principle, E6 may avoid competition with cellular factors by targeting both free and bound p53 molecules. The E6/E6AP/p53 complex represents a prototype of viral hijacking of both the ubiquitin-mediated protein degradation pathway and the p53 tumour suppressor pathway. The present structure provides a framework for the design of inhibitory therapeutic strategies against oncogenesis mediated by human papilloma virus.

8 February 2013 in Science
Verified
Journal Article
Closed access
PDF file
KZKatia Zanier
Katia Zanier
SCSebastian Charbonnier
Sebastian Charbonnier
ASAbdellahi Ould M'Hamed Ould Sidi
Abdellahi Ould M'Hamed Ould Sidi
AMAlastair Graham McEwen
Alastair Graham McEwen
MFMaria Giovanna Ferrario
Maria Giovanna Ferrario
GTGilles TRAVE
Gilles TRAVE
Targeting HPV: Papillomaviruses infect mammalian epithelial cells and induce cancers, including cervical cancer in humans. Vaccines against human papillomavirus (HPV) can prevent, but not cure, infection. A key viral oncoprotein, E6, acts by binding and inactivating many host proteins. Zanier et al. (p. 694 ) determined high-resolution crystal structures of bovine papillomavirus bound to a peptide from the focal adhesion protein, paxillin, and of HPV bound to a peptide from the ubiquitin ligase E6AP. The structures show that the peptide binds in a pocket formed by two zinc domains and a linker helix, which represents a promising target for therapeutics.

15 January 2018 in Viruses
Verified
Journal Article
Open access
PDF file
ISIrina Suarez
Irina Suarez
GTGilles TRAVE
Gilles TRAVE
Since their discovery in the mid-eighties, the main papillomavirus oncoproteins E6 and E7 have been recalcitrant to high-resolution structure analysis. However, in the last decade a wealth of three-dimensional information has been gained on both proteins whether free or complexed to host target proteins. Here, we first summarize the diverse activities of these small multifunctional oncoproteins. Next, we review the available structural data and the new insights they provide about the evolution of E6 and E7, their multiple interactions and their functional variability across human papillomavirus (HPV) species.

1 November 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KLKatja Luck
Katja Luck
SFSadek Fournane
Sadek Fournane
BKBruno Kieffer
Bruno Kieffer
MMMurielle Masson
Murielle Masson
YNYves Nominé
Yves Nominé
GTGilles TRAVE
Gilles TRAVE
PDZ domains recognise short sequence motifs at the extreme C-termini of proteins. A model based on microarray data has been recently published for predicting the binding preferences of PDZ domains to five residue long C-terminal sequences. Here we investigated the potential of this predictor for discovering novel protein interactions that involve PDZ domains. When tested on real negative data assembled from published literature, the predictor displayed a high false positive rate (FPR). We predicted and experimentally validated interactions between four PDZ domains derived from the human proteins MAGI1 and SCRIB and 19 peptides derived from human and viral C-termini of proteins. Measured binding intensities did not correlate with prediction scores, and the high FPR of the predictor was confirmed. Results indicate that limitations of the predictor may arise from an incomplete model definition and improper training of the model. Taking into account these limitations, we identified several novel putative interactions between PDZ domains of MAGI1 and SCRIB and the C-termini of the proteins FZD4, ARHGAP6, NET1, TANC1, GLUT7, MARCH3, MAS, ABC1, DLL1, TMEM215 and CYSLTR2. These proteins are localised to the membrane or suggested to act close to it and are often involved in G protein signalling. Furthermore, we showed that, while extension of minimal interacting domains or peptides toward tandem constructs or longer peptides never suppressed their ability to interact, the measured affinities and inferred specificity patterns often changed significantly. This suggests that if protein fragments interact, the full length proteins are also likely to interact, albeit possibly with altered affinities and specificities. Therefore, predictors dealing with protein fragments are promising tools for discovering protein interaction networks but their application to predict binding preferences within networks may be limited.

7 February 2011 in Bioinformatics
Verified
Journal Article
Open access
PDF file
KLKatja Luck
Katja Luck
GTGilles TRAVE
Gilles TRAVE
Motivation: The phage display peptide selection approach is widely used for defining binding specificities of globular domains. PDZ domains recognize partner proteins via C-terminal motifs and are often used as a model for interaction predictions. Here, we investigated to which extent phage display data that were recently published for 54 human PDZ domains can be applied to the prediction of human PDZ–peptide interactions. Results: Promising predictions were obtained for one-third of the 54 PDZ domains. For the other two-thirds, we detected in the phage display peptides an important bias for hydrophobic amino acids that seemed to impair correct predictions. Therefore, phage display-selected peptides may be over-hydrophobic and of high affinity, while natural interaction motifs are rather hydrophilic and mostly combine low affinity with high specificity. We suggest that potential amino acid composition bias should systematically be investigated when applying phage display data to the prediction of specific natural domain–linear motif interactions. Contact:katja.luck@unistra.fr; gilles.trave@unistra.fr Supplementary information: Supplementary data are available at Bioinformatics online.

17 June 2016 in Cell Cycle
Verified
Journal Article
Closed access
GTGilles TRAVE
Gilles TRAVE
KZKatia Zanier
Katia Zanier
Tumor suppressor p53 plays an essential role in preventing cancer development. In healthy cells p53 levels are kept low by degradation via the ubiquitin ligase Mdm2, whose gene expression is, in tu...